We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Ferrite Nanoparticles for Hyperthermic Cancer Therapeutics

By LabMedica International staff writers
Posted on 08 Nov 2017
A novel type of nontoxic magnetic nanoparticles shows potential for treating malignant tumor cells through controlled hyperthermia.

For hyperthermia to be used under clinical conditions for cancer therapeutics the temperature regulation needs to be precise and accurately controllable. More...
In the case of the metal nanoparticles used for such activities, a high coercivity is a prerequisite in order to couple more energy in a single heating cycle for efficient and faster differential heating. Coercivity is a measure of the ability of a ferromagnetic material to withstand an external magnetic field without becoming demagnetized.

Ferromagnetic materials with high coercivity are called magnetically hard materials, and are used to make permanent magnets. Materials with low coercivity are said to be magnetically soft. The latter are used in transformer and inductor cores, recording heads, microwave devices, and magnetic shielding.

Chemically stable Co–Zn ferrite nanoparticles have typically not been used in self-regulating hyperthermia temperature applications to date due to their low Curie temperature (the temperature at which certain materials lose their permanent magnetic properties), usually accompanied by a poor coercivity.

Tumor cells can be attacked and killed by hyperthermic nanoparticles without affecting normal tissue if the temperature of the particles can be controlled accurately within a range of 42°C to 45°C. To accomplish this task, investigators at the University of Surrey (United Kingdom) developed novel Cr3+ substituted Co–Zn ferrite nanoparticles, whose Curie temperature was 45.7 °C. Under clinically acceptable magnetic field conditions, the temperature of these nanoparticle suspensions could be self-regulated to 44.0°C.

The investigators reported in the October 7, 2017, issue of the journal Nanoscale that evaluation of the in vitro cytotoxicity of the nanoparticles showed a low toxicity, which indicated that this novel set of magnetic nanoparticles should be appropriate for use in self-regulating hyperthermia therapeutics.

Senior author Dr. Ravi Silva, head of the advanced technology institute at the University of Surrey, said, "This could potentially be a game changer in the way we treat people who have cancer. If we can keep cancer treatment sat at a temperature level high enough to kill the cancer, while low enough to stop harming healthy tissue, it will prevent some of the serious side effects of vital treatment. It is a very exciting development which, once again, shows that the University of Surrey research is at the forefront of nanotechnologies - whether in the field of energy materials or, in this case, healthcare."

Related Links:
University of Surrey


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.